World's Best Scientists 2026 revealed!
Edith A. Perez

Edith A. Perez

Award Badge
Best Female Scientists
2025

D-Index & Metrics

Best Female Scientists

D-Index
117
Citations
79441
World Ranking
627
National Ranking
382

Medicine

D-Index
117
Citations
81667
World Ranking
4116
National Ranking
2252

Research.com Recognitions

  • 2025 - Research.com Best Female Scientists Award

Overview

Edith A. Perez is affiliated with the Mayo Clinic in the United States and has an extensive publication record in medicine, particularly focusing on oncology and cancer research. Their work spans several subfields including oncology, cancer research, radiology, nuclear medicine and imaging, pulmonary and respiratory medicine, and molecular biology.

The scientific contributions of Edith A. Perez include numerous papers addressing breast cancer treatment and cancer immunotherapy. Some of the recent publications by this researcher are:

  • Abstract GS3-00: First results from a phase III randomized clinical trial of standard adjuvant endocrine therapy (ET) +/- chemotherapy (CT) in patients (pts) with 1-3 positive nodes, hormone receptor-positive (HR+) and HER2-negative (HER2-) breast cancer (BC) with recurrence score (RS) < 25: SWOG S1007 (RxPonder), 2021, Cancer Research
  • Folate receptor alpha expression associates with improved disease-free survival in triple negative breast cancer patients, 2020, npj Breast Cancer
  • Diversity, Equity, and Inclusion in Nursing, 2021, Nursing Administration Quarterly
  • Preliminary results from a phase 1/2 study of BDC-1001, a novel HER2 targeting TLR7/8 immune-stimulating antibody conjugate (ISAC), in patients (pts) with advanced HER2-expressing solid tumors., 2021, Journal of Clinical Oncology
  • Distinct spatial immune microlandscapes are independently associated with outcomes in triple-negative breast cancer, 2023, Nature Communications

The main research topics covered by Edith A. Perez include:

  • Breast Cancer Treatment Studies
  • Cancer Immunotherapy and Biomarkers
  • Cancer Treatment and Pharmacology
  • HER2/EGFR in Cancer Research
  • Advanced Breast Cancer Therapies
  • Monoclonal and Polyclonal Antibodies Research
  • Cancer Genomics and Diagnostics

The researcher frequently publishes in the following academic venues:

  • Cancer Research
  • Journal of Clinical Oncology
  • Breast Cancer Research and Treatment
  • UNC Libraries
  • npj Breast Cancer

Collaboration is a significant aspect of Edith A. Perez's research, with recurring co-authors including:

  • Saranya Chumsri
  • Alvaro Moreno-Aspitia
  • E. Aubrey Thompson
  • Keith L. Knutson
  • Yaohua Ma

Throughout their career, Edith A. Perez has contributed to advancing knowledge in cancer therapies and diagnostics, particularly focusing on breast cancer treatment strategies and the biological mechanisms involving HER2 and immune response. Their work integrates clinical studies and molecular biology approaches to address treatment outcomes and disease progression.

Best Publications

  • Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer

    Edward H. Romond;Edith A. Perez;John Bryant;Vera J. Suman

  • American society of clinical oncology/college of american pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer

    Antonio C. Wolff;M. Elizabeth H. Hammond;Jared N. Schwartz;Karen L. Hagerty

  • American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer.

    Antonio C. Wolff;M. Elizabeth H. Hammond;Jared N. Schwartz;Karen L. Hagerty

  • Paclitaxel plus Bevacizumab versus Paclitaxel Alone for Metastatic Breast Cancer

    Kathy Miller;Molin Wang;Julie Gralow;Maura Dickler

  • A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer

    Paul E. Goss;James N. Ingle;Silvana Martino;Nicholas J. Robert

  • Randomized Trial of Dose-Dense Versus Conventionally Scheduled and Sequential Versus Concurrent Combination Chemotherapy as Postoperative Adjuvant Treatment of Node-Positive Primary Breast Cancer: First Report of Intergroup Trial C9741/Cancer and Leukemia Group B Trial 9741

    Marc L. Citron;Donald A. Berry;Constance Cirrincione;Clifford Hudis

  • Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer on chemotherapy: a retrospective analysis of a randomised trial

    Kathy S Albain;William E Barlow;Steven Shak;Gabriel N Hortobagyi

  • Prospective Validation of a 21-Gene Expression Assay in Breast Cancer

    J. A. Sparano;R. J. Gray;D. F. Makower;K. I. Pritchard

  • Randomized Trial of Letrozole Following Tamoxifen as Extended Adjuvant Therapy in Receptor-Positive Breast Cancer: Updated Findings from NCIC CTG MA.17

    Paul E. Goss;James N. Ingle;Silvana Martino;Nicholas J. Robert

  • RIBBON-1: Randomized, Double-Blind, Placebo-Controlled, Phase III Trial of Chemotherapy With or Without Bevacizumab for First-Line Treatment of Human Epidermal Growth Factor Receptor 2–Negative, Locally Recurrent or Metastatic Breast Cancer

    Nicholas J. Robert;Véronique Diéras;John Glaspy;Adam M. Brufsky

  • Weekly Paclitaxel in the Adjuvant Treatment of Breast Cancer

    Joseph A. Sparano;Joseph A. Sparano;Molin Wang;Silvana Martino;Vicky Jones

  • Trastuzumab Plus Adjuvant Chemotherapy for Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer: Planned Joint Analysis of Overall Survival From NSABP B-31 and NCCTG N9831

    Edith A. Perez;Edward H. Romond;Vera J. Suman;Jong Hyeon Jeong

  • Treatment of HER2-positive breast cancer: current status and future perspectives

    Carlos L. Arteaga;Mark X. Sliwkowski;C. Kent Osborne;Edith A. Perez

  • Pharmacogenetics of Tamoxifen Biotransformation Is Associated With Clinical Outcomes of Efficacy and Hot Flashes

    Matthew P. Goetz;James M. Rae;Vera J. Suman;Stephanie L. Safgren

  • Four-Year Follow-Up of Trastuzumab Plus Adjuvant Chemotherapy for Operable Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer: Joint Analysis of Data From NCCTG N9831 and NSABP B-31

    Edith A. Perez;Edward H. Romond;Vera J. Suman;Jong Hyeon Jeong

  • Association of Vascular Endothelial Growth Factor and Vascular Endothelial Growth Factor Receptor-2 Genetic Polymorphisms With Outcome in a Trial of Paclitaxel Compared With Paclitaxel Plus Bevacizumab in Advanced Breast Cancer: ECOG 2100

    Bryan P. Schneider;Molin Wang;Milan Radovich;George W. Sledge

  • Adjuvant Exemestane with Ovarian Suppression in Premenopausal Breast Cancer

    Olivia Pagani;Meredith M. Regan;Barbara A. Walley;Gini F. Fleming

  • Adjuvant bisphosphonate treatment in early breast cancer: meta-analyses of individual patient data from randomised trials

    J. Bergh;K. Pritchard;K. Albain;S. Anderson

  • Cardiac Safety Analysis of Doxorubicin and Cyclophosphamide Followed by Paclitaxel With or Without Trastuzumab in the North Central Cancer Treatment Group N9831 Adjuvant Breast Cancer Trial

    Edith A. Perez;Vera J. Suman;Nancy E. Davidson;George W. Sledge

  • The impact of cytochrome P450 2D6 metabolism in women receiving adjuvant tamoxifen.

    Matthew P. Goetz;Stacey K. Knox;Vera J. Suman;James M. Rae

Frequent Co-Authors

James N. Ingle
James N. Ingle Mayo Clinic
Nancy E. Davidson
Nancy E. Davidson University of Washington
Amylou C. Dueck
Amylou C. Dueck Mayo Clinic
Yan W. Asmann
Yan W. Asmann Mayo Clinic
Karla V. Ballman
Karla V. Ballman Cornell University
Joseph A. Sparano
Joseph A. Sparano Albert Einstein College of Medicine
Vera J. Suman
Vera J. Suman Mayo Clinic
Kathleen I. Pritchard
Kathleen I. Pritchard University of Toronto

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Exploring Medicine in the USA opens doors to various rewarding healthcare careers, some of which can be started or advanced with online degrees and certifications. For those looking to practice advanced nursing, enrolling in one of the cheapest dnp programs online can be a cost-effective route, leading to leadership and specialist roles in clinical care.

If pharmacy interests you, there are top-rated online pharmacist programs that offer a flexible pathway to this high-demand profession. Similarly, the healthcare industry needs tech-savvy professionals to manage patient data. Completing one of the accredited healthcare informatics degree programs can lead to vital roles in digital recordkeeping and data analysis.

For those interested in administrative healthcare roles, consider the field of medical coding. You can quickly gain in-demand skills by enrolling in billing and coding classes online, which lead to entry-level positions with strong job prospects.

Whether your passion lies in direct patient care, pharmaceutical work, informatics, or administration, these online pathways offer flexibility and affordability, helping you build a meaningful healthcare career.

Best Scientists Citing Edith A. Perez

Trending Scientists